Daina Graybosch
Stock Analyst at Leerink Partners
(0.08)
# 4,600
Out of 4,644 analysts
498
Total ratings
39%
Success rate
-7.8%
Average return
Main Sectors:
Stocks Rated by Daina Graybosch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IPHA Innate Pharma | Upgraded: Buy | $2 → $4 | $2.15 | +86.05% | 33 | Aug 11, 2026 | |
| REPL Replimune Group | Upgraded: Buy | $17 | $13.65 | +24.54% | 1 | Aug 3, 2026 | |
| GILD Gilead Sciences | Downgraded: Hold | $129 → $127 | $135.77 | -6.46% | 29 | Jul 20, 2026 | |
| CGEN Compugen | Maintained: Buy | $13 → $5 | $2.40 | +108.33% | 28 | May 21, 2026 | |
| RCUS Arcus Biosciences | Maintained: Buy | $49 → $47 | $28.74 | +63.54% | 25 | Apr 20, 2026 | |
| BNTX BioNTech SE | Downgraded: Hold | $107 → $113 | $92.80 | +21.77% | 67 | Feb 2, 2026 | |
| MRK Merck & Co. | Maintained: Buy | $107 → $114 | $130.42 | -12.59% | 77 | Dec 15, 2025 | |
| IPSC Century Therapeutics | Downgraded: Hold | $7 → $2 | $2.06 | -2.91% | 26 | Nov 17, 2025 | |
| SMMT Summit Therapeutics | Maintained: Sell | n/a | $15.12 | - | 7 | Oct 22, 2025 | |
| NBP NovaBridge Biosciences | Initiated Coverage: Buy | $9 | $1.84 | +389.13% | 1 | Oct 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 → $7 | $2.74 | +155.47% | 37 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $20 → $6 | $3.98 | +50.75% | 21 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 → $10 | $0.3837 | +2,506.20% | 20 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $28 | $9.18 | +205.01% | 2 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8 | $2.33 | n/a | 20 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $3.89 | n/a | 2 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $5 → $0.39 | $0.0001 | n/a | 32 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $6 | $4.20 | n/a | 19 | Aug 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $74.58 | n/a | 1 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1.5 | $75.50 | n/a | 26 | Sep 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $5.10 | n/a | 1 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | $0.0001 | n/a | 10 | Apr 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $25 → $1.8 | $5.95 | n/a | 8 | Apr 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | CHF 35.00 | CHF 3.28 | n/a | 1 | Apr 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €82.34 → €86.67 | €138.90 | n/a | 3 | Aug 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $5 | $76.87 | n/a | 1 | May 22, 2019 |
Innate Pharma
Aug 11, 2026
Upgraded: Buy
Price Target: $2 → $4
Current: $2.15
Upside: +86.05%
Replimune Group
Aug 3, 2026
Upgraded: Buy
Price Target: $17
Current: $13.65
Upside: +24.54%
Gilead Sciences
Jul 20, 2026
Downgraded: Hold
Price Target: $129 → $127
Current: $135.77
Upside: -6.46%
Compugen
May 21, 2026
Maintained: Buy
Price Target: $13 → $5
Current: $2.40
Upside: +108.33%
Arcus Biosciences
Apr 20, 2026
Maintained: Buy
Price Target: $49 → $47
Current: $28.74
Upside: +63.54%
BioNTech SE
Feb 2, 2026
Downgraded: Hold
Price Target: $107 → $113
Current: $92.80
Upside: +21.77%
Merck & Co.
Dec 15, 2025
Maintained: Buy
Price Target: $107 → $114
Current: $130.42
Upside: -12.59%
Century Therapeutics
Nov 17, 2025
Downgraded: Hold
Price Target: $7 → $2
Current: $2.06
Upside: -2.91%
Summit Therapeutics
Oct 22, 2025
Maintained: Sell
Price Target: n/a
Current: $15.12
Upside: -
NovaBridge Biosciences
Oct 6, 2025
Initiated Coverage: Buy
Price Target: $9
Current: $1.84
Upside: +389.13%
Sep 4, 2025
Maintained: Buy
Price Target: $12 → $7
Current: $2.74
Upside: +155.47%
Sep 4, 2025
Maintained: Hold
Price Target: $20 → $6
Current: $3.98
Upside: +50.75%
Sep 4, 2025
Reiterated: Buy
Price Target: $12 → $10
Current: $0.3837
Upside: +2,506.20%
Aug 15, 2025
Reiterated: Buy
Price Target: $28
Current: $9.18
Upside: +205.01%
Aug 13, 2025
Maintained: Buy
Price Target: $8
Current: $2.33
Upside: n/a
Aug 13, 2025
Reiterated: Buy
Price Target: $7
Current: $3.89
Upside: n/a
May 14, 2025
Downgraded: Hold
Price Target: $5 → $0.39
Current: $0.0001
Upside: n/a
Aug 28, 2024
Maintained: Hold
Price Target: $6
Current: $4.20
Upside: n/a
Dec 11, 2023
Maintained: Buy
Price Target: n/a
Current: $74.58
Upside: n/a
Sep 15, 2023
Maintained: Hold
Price Target: $1.5
Current: $75.50
Upside: n/a
Jun 5, 2023
Maintained: Buy
Price Target: n/a
Current: $5.10
Upside: n/a
Apr 27, 2022
Maintained: Buy
Price Target: $5
Current: $0.0001
Upside: n/a
Apr 1, 2022
Downgraded: Hold
Price Target: $25 → $1.8
Current: $5.95
Upside: n/a
Apr 6, 2021
Maintained: Buy
Price Target: CHF 35.00
Current: CHF 3.28
Upside: n/a
Aug 25, 2020
Maintained: Buy
Price Target: €82.34 → €86.67
Current: €138.90
Upside: n/a
May 22, 2019
Maintained: Hold
Price Target: $5
Current: $76.87
Upside: n/a